Skip to content

OWP Pharmaceuticals Announces Patent Issuance for the First-Ever Oral Liquid Suspension of Quetiapine for the Treatment of Schizophrenia and Bipolar Disorder

Share this press release:

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use